

# Innocan Pharma Announces the Filing of a PCT Patent Application for its CBD Delivery System Technology in 153 Countries

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 4, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "**Company**" or "**Innocan**"), is pleased to announce that a new patent application has been filed for Innocan's CBD Delivery System Technology, alongside the existing LTP (CBD Loaded Liposomes) and CLX (CBD Loaded Exosomes). The new patent application discloses a unique and novel delivery system allowing the controlled release of CBD into the blood stream with improved pharmacokinetic (PK) performance.

This patent application is a significant milestone in the research conducted in collaboration with the Hebrew University, that indicates the potential of the Company's technological ability to deliver cannabinoids to the blood stream in precise and effective administration.




Figure 1: Free CBD injected intravenously (red line) rapidly eliminated from the plasma vs the new CBD slow and controlled release Delivery System administered subcutaneously allowing exposure to CBD for at least 3 weeks after one injection

To view an enhanced version of Figure 1, please visit:  
[https://orders.newsfilecorp.com/files/6922/98533\\_fig1.jpg](https://orders.newsfilecorp.com/files/6922/98533_fig1.jpg)

Prolonged and controlled release of Cannabidiol (CBD) from Innocan's novel Delivery System injected subcutaneously, showed continuous clinically relevant concentrations of CBD in the blood for a long time. The Company believes this is considered a good predictor to the expected CBD exposure in humans.

The Company believes that the continuous exposure to CBD in blood for a longer time post local administration, seems to be superior to orally administered CBD in two aspects: (a) it will all allow a single administration of CBD instead of daily administration; and (b) it will overcome the low (10-20%) oral bioavailability of CBD. The superior PK of the CBD Delivery System administered, may achieve controlled concentration of CBD in the blood leading to a better clinical outcome.

Prof. Chezy Barenholz of The Hebrew University of Jerusalem said, "*The filing of this PCT is an*

*additional step towards our R&D scientific achievement." Barenholz added, "We are proud to enable the cutting-edge solutions that may serve as the foundation to CBD Pharma in the future."*

"The publication of the PCT patent applications reaffirms the novelty of our approach and advantage," said Iris Bincovich, CEO of Innocan, and added, "We continue to test on this patent-pending CBD Delivery System to further validate its superior efficacy and safety profile."

### **Innocan's relationship with The Hebrew University**

Innocan Pharma Ltd., a wholly owned subsidiary of the Company, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company ("**Yissum**"), the commercial arm of The Hebrew University of Jerusalem, with respect to the design, preparation, characterization, and evaluation of hydrogels containing CBD (or other cannabinoids) loaded liposomes. The research and development initiative are led by Professor Chezy Barenholz, head of the Membrane and Liposome Research Laboratory at The Hebrew University-Hadassah Medical School which is the inventor of over fifty-five patent families, two of which underlie Doxil®, a liposome based the first FDA-approved nano-drug for ovarian and other cancers' treatment, used globally. Innocan's novel and unique platform technology for slow and controlled release of CBD may have a wide range of applications, such as epilepsy, pain relief, inflammation, and central nervous system disorders. A patent application was filed covering this technology on September 30, 2021.

### **About Innocan**

Innocan, together with its wholly-owned subsidiary, Innocan Pharma Ltd. ("**Innocan Israel**") is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administered by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-and novel controlled slow-release technologies to be administered by injection. Innocan Israel plans, together with Professor Barenholz, to test both the above novel platform and the previously developed liposome platform (PCT filed on October 01, 2020) on several potential conditions. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:

Iris Bincovich, CEO

+972-54-3012842

[info@innocanpharma.com](mailto:info@innocanpharma.com)

Lytham Partners, LLC

Ben Shamsian CPA | Vice President

Direct: 646-829-9701; Cell: 516-652-9004`Shamsian

[shamsian@lythampartners.com](mailto:shamsian@lythampartners.com)

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

#### Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals, the granting of patents underlying the patent applications and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; intellectual property risks, and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at [www.sedar.com](http://www.sedar.com).

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/98533>